Contact Us

Consumer Services or Programs

If your question is about a medical condition, then you should consult with a healthcare professional or, in the case of an emergency, call 911 immediately.

Standard business hours for CSL Behring are 8:30 am to 5:00 pm eastern time.

CSL Behring Headquarters Phone: 610-878-4000 Fax: 610-878-4009 Location: North America Headquarters Address: P.O. Box 61501 1020 First Avenue King of Prussia, PA 19406 USA

Consumer Affairs For Consumer Information Phone: 888-508-6978 Fax: 610-878-4008   Medical Affairs Phone: 800-504-5434 Fax: 610-878-4007   Adverse Events Phone: 610-878-4193 Phone (After Business Hours): 866-915-6958

All fields marked with an asterisk (*) are required.
*To ensure that your question or comment is directed to the appropriate CSL Behring department, please select one of these choices:
		Medical Inquiries About Humate-P® Comments about HumateP.com
*Salutation:		Dr. Mr. Mrs. Ms.
*First Name:
*Last Name:
*I am a:		Patient Family Member Caregiver or Friend Healthcare Professional Other
*Other, please explain:
*E-mail Address:
*Confirm E-mail Address:
Please enter your comments:
*Type in the verification word in the box below and hit "Submit":
Prior to submitting your information, please review our Privacy Policy.

 

Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P^® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P^® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P^® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P^® is derived from human plasma. As with all plasma-derived products, the risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Although few adverse reactions have been reported the most common are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see accompanying full prescribing information for Humate-P^®.